- Home
- BDTX vs SITC Comparison
BDTX vs SITC Comparison
Compare BDTX & SITC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | SITC |
|---|---|---|
| Founded | 2014 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 154.8M |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | BDTX | SITC |
|---|---|---|
| Price | $1.90 | $3.75 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 761.0K | ★ 2.1M |
| Earning Date | 11-05-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 106.95% |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $123,649,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $2.80 |
| 52 Week High | $4.94 | $8.91 |
Technical Indicators
Market Signals| Indicator | BDTX | SITC |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 72.09 |
| Support Level | $1.79 | $2.89 |
| Resistance Level | $1.93 | $4.55 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 50.93 | 88.56 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.